Navigation Links
PDL BioPharma Receives Letter from Genentech Relating to European Patents
Date:8/13/2010

INCLINE VILLAGE, Nev., Aug. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" section of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx BioPharma Completes $13 Million Series C Financing
2. Almac Launch Biomarkers for Biopharma
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
5. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
6. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
7. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
8. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
9. PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010
10. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
(Date:8/4/2017)... Aug. 4, 2017 The search for test ... a physician/patient consult has long been the goal of ... notable focus of the largest meeting of lab professionals ... healthcare market research firm Kalorama Information.  The firm said ... offerings or related supplies and software were at the ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... 17, 2017 , ... The award-winning producers of the Innovations ... Council for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth quarter 2017. ... a non-profit, international organization dedicated to professional excellence for the protection of consumers ...
(Date:8/17/2017)... ... ... Georgia Urology, the largest urology practice in the Southeastern United ... in East Cobb (4800 Olde Towne Parkway, Suite 220, Marietta). , “Georgia ... Haber, Georgia Urology’s managing partner. “She brings a passionate, fresh perspective on general urology ...
(Date:8/17/2017)... ... 17, 2017 , ... The 2017 Integrated Delivery Network (IDN) ... interact with their GPO and supplier partners. This year, Winifred Hayes, RN, PhD, ... of Clinical Value Analytics, have been invited to present “Episode-based Reimbursement and the ...
(Date:8/17/2017)... ... ... In its just released 2018 Edition, The Best Lawyers in America named ... consecutive year that Hardiman and Mills have been honored and the seventh year in ... Care Law while Mills was recognized in the Administrative and Regulatory Law category. ...
(Date:8/17/2017)... Angeles, California (PRWEB) , ... August 17, 2017 , ... ... the number of South Korean men obtaining plastic surgery, largely influenced by the growing ... and beauty clinic Beverly Hills Physicians notes that standards of male appearance are changing ...
Breaking Medicine News(10 mins):